Biotest’s largest minority shareholder criticizes Grifols’ plan to exclude its German subsidiary from the stock market

The Westbourne River fund, the largest minority shareholder of Biotest, has criticized Grifols’ plan to exclude its German subsidiary from the stock market, as reported by the entity in a letter to which Europe Press has had access on Tuesday. In this context, Westbourne River has insisted that they are "deeply concerned" about the decision of the board of directors, of Biotest, to support the exclusion of the stock market.